Stifel raised the firm’s price target on Johnson & Johnson to $190 from $165 and keeps a Hold rating on the shares after the company delivered above-consensus sales and EPS, offered up “bullish” commentary and “repeatedly emphasized their optimism” about the rest-of-2025 outlook and their confidence that the business is now in an “accelerated cycle of growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Hold Recommendation for Johnson & Johnson Amid Modest Earnings Beat and Strategic Spin-Off Plans
- Johnson & Johnson Reports Strong Q3 2025 Performance
- Johnson & Johnson’s Earnings Call Highlights Growth and Strategy
- Johnson & Johnson price target raised to $215 from $213 at Citi
- Johnson & Johnson price target raised to $222 from $185 at TD Cowen